Rising geriatric population and growing prevalence of Geographic Atrophy are projected to fuels the growth of the global Geographic Atrophy Market at a CAGR of 7.5% during the forecast period 2023 to 2030.

Market Research Future (MRFR) has published a cooked research report on the “Global Geographic Atrophy Market” that contains the information from 2023 to 2030. The Geographic Atrophy Market is projected to register a CAGR of 7.5% during the forecast period of 2023 to 2030.

Market Highlights

The global Geographic Atrophy Market is accounted to register a CAGR of 7.5% during the forecast period and is estimated to reach USD 35.80 billion by 2030.

The Geographic Atrophy Market will witness a steady growth during the forecast period. The anticipated high growth within the market can be attributed to the rising geriatric population and growing prevalence of Geographic Atrophy. Unfortunately, the market witnesses few setbacks owing to the lack of availability of Geographic Atrophy treatment. The market does have extensive research activities and fundings to fuel the same. However, there has been no mode of treating the conditions that are approved which acts the current threshold.

Nevertheless, it is anticipated that the with the current research & development investment by pharmaceutical & biotechnology companies, the market space would soon achieve a breakthrough that would push for create lucrative opportunities for the players operating in the global Geographic Atrophy Market.

Key Players

MRFR recognizes the following companies as the key players in the global Geographic Atrophy Market— F. Hoffmann-La Roche AG (Switzerland), Apellis Pharmaceuticals (US), IVERIC bio, Inc. (US), Alkeus Pharmaceuticals (US), Hemera Biosciences LLC (US), NGM Biopharmaceuticals (US), Johnson & Johnson Services, Inc. (US), AstraZeneca (UK), Novartis AG (Switzerland), Stealth BioTherapeutics Inc. (US), and others.

Segment Analysis

The global Geographic Atrophy Market has been segmented based on age group, diagnosis, and therapeutics agent’s clinical phase.

Based on age group, the global Geographic Atrophy Market has been segmented into less than 65 years, 65-74 years, 75-84 years, 85 years and above. 75-84 Years held the largest market share and contributed USD 4,723.67 million in 2022, and 85 years and above is anticipated to register the highest CAGR of 8.39% from 2023 to 2030.

Based on diagnosis, the global Geographic Atrophy Market has been segmented into fundus autofluorescence (FAF), optical coherence tomography angiography (OCT-A), and multifocal electroretinography (mfERG). Optical coherence tomography angiography (OCT-A) held the largest market share in 2022 and is anticipated to register the highest CAGR of 8.30% from 2023 to 2030.

Based on therapeutic agent’s clinical phase, the global Geographic Atrophy Market has been classified as late-stage (phase III), phase II, phase I, and pre-clinical stage & discovery candidates. Late-Stage (Phase III) held the largest market share and contributed USD 11,058.78 million in 2022 and is anticipated to register the highest CAGR of 8.23% from 2023 to 2030.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Geographic Atrophy (GA) Market Research Report

Regional Analysis

The global Geographic Atrophy Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and Middle East & Africa. Americas includes North America and Central & South America. The Americas further includes US, Canada, and Mexico and Central & South America includes Brazil, Argentina, Chile, and Rest of Central & South America. The Europe includes countries namely Germany, France, UK, Italy, Spain Netherlands, Denmark, and Rest of Europe. The Geographic Atrophy Market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, Taiwan, and Rest of Asia-Pacific. Moreover, the Middle East & Africa Geographic Atrophy Market comprises of UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa.

The Americas geography atrophy market is driving owing to the rising prevalence of age-related macular diseases, increasing investment in the healthcare industry, and the presence of major key players. Moreover, the rising number of patients suffering from Geographic Atrophy and growing government initiatives related to Geographic Atrophy in the region further fuel the growth of the market.

Europe has the second-largest market share due to increased accessibility to advanced treatment facilities, a growing patient population, and a growing demand for technologically innovative treatments, which are driving demand for Geographic Atrophy in Europe.

The India and China are majorly contributing to the Asia-Pacific Geographic Atrophy Market growth. Additionally, rising healthcare infrastructure and the growing demand for improved healthcare services are also expected to boost the growth of the regional market. Moreover, companies involved in research & development, commercialization of products from this region include Santen Pharmaceuticals Inc. (Japan), and Ocumension Therapeutics (Shanghai) Co., Ltd. (China) presence of these players in the region is boosting the market growth of Asia-Pacific Geographic Atrophy Market.

The Middle East, and Africa is segmented into the UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa. The Geographic Atrophy Market in the above-mentioned regions is likely to witness growth due to improving healthcare facilities, technological advancements, and the increasing burden of the geriatric population. Moreover, the interactive dashboard of the International Agency for the Prevention of Blindness (IAPB) displays the crude prevalence of vision impairment to be highest in the Middle East and Africa.

Key Findings of the Study

• The global Geographic Atrophy Market is expected to reach USD 14.81 billion by 2030 at a CAGR of 7.32% during the forecast period.


• The Europe region held the second largest market share of the global market, owing to a growing patient population, and a growing demand for technologically innovative treatments.


• Based on diagnosis, the OCT-A held the largest market in 2022, with a market share of 66.73%.


• Hoffmann-La Roche AG (Switzerland), Apellis Pharmaceuticals (US), IVERIC bio, Inc. (US), Alkeus Pharmaceuticals (US), Hemera Biosciences LLC (US), NGM Biopharmaceuticals (US), Johnson & Johnson Services, Inc. (US), AstraZeneca (UK), Novartis AG (Switzerland), Stealth BioTherapeutics Inc. (US), and others are the key players in the market.